Skip to main content
OpenTrials

Clinical trial condition

Smoldering Multiple Myeloma

Explore clinical trials studying Smoldering Multiple Myeloma. Study availability and eligibility vary by location and protocol.

43 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Smoldering Multiple Myeloma trial results

Completed

Imaging in MGUS, SMM and MM

NCT01237054

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
View Trial Details
Completed

Screening to Improve Survival in AL Amyloidosis

NCT04615572

Conditions
Amyloidosis, Blood Protein Disorders, Hematologic Diseases, +16 more
Locations
  • University of California, Irvine Health Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Tufts Medical Center Boston, Massachusetts, United States
View Trial Details
Completed

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • St Francis Hospital and Medical Center Hartford, Connecticut, United States
  • University of Chicago Chicago, Illinois, United States
  • Eastern Maine Medical Center Brewer, Maine, United States
View Trial Details
Completed

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

NCT01302886

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Highlands Oncology Group Dept of Highlands Oncology Grp Fayetteville, Arkansas, United States
  • H. Lee Moffitt Cancer Center & Research Institute SC - 3 Tampa, Florida, United States
  • Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) Atlanta, Georgia, United States
  • Indiana University Indiana Univ Indianapolis, Indiana, United States
View all 13 locations
View Trial Details
Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

NCT01441973

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Sharp Clinical Oncology Research San Diego, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Va Connecticut Healthcare System West Haven, Connecticut, United States
  • Winship Cancer Institute. Atlanta, Georgia, United States
View Trial Details

Related conditions